文献速递冠心病心律失常血脂与心血管预防

多基因风险评分用于心脏代谢疾病预测

Polygenic risk scores for the prediction of cardiometabolic disease.
PubMed 文献 · Eur Heart J · 2023-01-01

本文综述了多基因风险评分(PRS)在七种常见心脏代谢疾病中的预测证据。数据提示,将PRS纳入现有临床风险工具可一致改善冠心病、房颤和2型糖尿病的预测;在缺血性卒中和高血压等领域,临床应用尚不成熟。

要点

  • PRS是微效遗传变异的加权和,可提升心脏代谢疾病预测能力。
  • 冠心病、房颤和2型糖尿病的PRS在现有工具基础上一致改善预测。
  • 缺血性卒中和高血压的PRS临床应用尚早,需更大更多样人群研究。

核心结论

  • PRS在冠心病、房颤和2型糖尿病中纳入现有临床风险工具可一致改善预测。
  • 在缺血性卒中和高血压中临床应用尚不成熟,但更大更多样人群和更精细表型研究将推动转化。

研究设计与样本

  • 本文为综述,回顾PRS在七种常见心脏代谢疾病中预测应用的证据。

主要发现

  • 数据提示冠心病、房颤和2型糖尿病的PRS纳入现有临床风险工具可一致改善预测。
  • 缺血性卒中和高血压的临床应用 appears premature,但新兴证据提示更大更多样人群和更精细表型研究将推动PRS转化为实用临床预测工具。

临床怎么用

  • 可考虑将PRS纳入冠心病、房颤和2型糖尿病的现有临床风险工具以改善预测。
  • 缺血性卒中和高血压的PRS暂不推荐用于临床预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiometabolic diseases contribute more to global morbidity and mortality than any other group of disorders. Polygenic risk scores (PRSs), the weighted summation of individually small-effect genetic variants, represent an advance in our ability to predict the development and complications of cardiometabolic diseases. This article reviews the evidence supporting the use of PRS in seven common cardiometabolic diseases: coronary artery disease (CAD), stroke, hypertension, heart failure and cardiomyopathies, obesity, atrial fibrillation (AF), and type 2 diabetes mellitus (T2DM). Data suggest that PRS for CAD, AF, and T2DM consistently improves prediction when incorporated into existing clinical risk tools. In other areas such as ischaemic stroke and hypertension, clinical application appears premature but emerging evidence suggests that the study of larger and more diverse populations coupled with more granular phenotyping will propel the translation of PRS into practical clinical prediction tools.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. O'Sullivan JW, Ashley EA, Elliott PM, et al. Polygenic risk scores for the prediction of cardiometabolic disease. Eur Heart J. 2023. PMID: 36478054. doi:10.1093/eurheartj/ehac648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。